Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells

Muramatsu,Hiroyuki; Sumitomo,Makoto; Morinaga,Shingo; Kajikawa,Keishi; Kobayashi,Ikuo; Nishikawa,Genya; Kato,Yoshiharu; Watanabe,Masahito; Zennami,Kenji; Kanao,Kent; Nakamura,Kogenta; Suzuki,Susumu; Yoshikawa,Kazuhiro

doi:10.3892/or.2019.7171

Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells

Authors:
- Hiroyuki Muramatsu
- Makoto Sumitomo
- Shingo Morinaga
- Keishi Kajikawa
- Ikuo Kobayashi
- Genya Nishikawa
- Yoshiharu Kato
- Masahito Watanabe
- Kenji Zennami
- Kent Kanao
- Kogenta Nakamura
- Susumu Suzuki
- Kazuhiro Yoshikawa
View Affiliations

Affiliations: Department of Urology, Aichi Medical University School of Medicine, Nagakute 480‑1195, Japan, Division of Research Support, Research Creation Support Center, Aichi Medical University, Nagakute 480‑1195, Japan, Division of Research Creation, Research Creation Support Center, Aichi Medical University, Nagakute 480‑1195, Japan
Published online on: May 24, 2019 https://doi.org/10.3892/or.2019.7171
Pages: 224-230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Docetaxel (DOC) is one of the most effective chemotherapeutic agents against castration‑resistant prostate cancer (CRPC). Despite an impressive initial clinical response, the majority of patients eventually develop resistance to DOC. In tumor metabolism, where tumors preferentially utilize anaerobic metabolism, lactate dehydrogenase (LDH) serves an important role. LDH controls the conversion of pyruvate to lactate, with LDH‑A, one of the predominant isoforms of LDH, controlling this metabolic process. In the present study, the role of LDH‑A in drug resistance of human prostate cancer (PC) was examined by analyzing 4 PC cell lines, including castration‑providing strains PC3, DU145, LNCaP and LN‑CSS (which is a hormone refractory cell line established from LNCaP). Sodium oxamate (SO) was used as a specific LDH‑A inhibitor. Changes in the expression level of LDH‑A were analyzed by western blotting. Cell growth and survival were evaluated with a WST‑1 assay. Cell cycle progression and apoptotic inducibility were evaluated by flow cytometry using propidium iodide and Annexin V staining. LDH expression was strongly associated with DOC sensitivity in PC cells. SO inhibited growth of PC cells, which was considered to be caused by the inhibition of LDH‑A expression. Synergistic cytotoxicity was observed by combining DOC and SO in LN‑CSS cells, but not in LNCaP cells. This combination treatment induced additive cytotoxic effects in PC‑3 and DU145 cells, caused cell cycle arrest in G2‑M phase and increased the number of cells in the sub‑G1 phase of cell cycle in LN‑CSS cells. SO promoted DOC induced apoptosis in LN‑CSS cells, which was partially caused by the inhibition of DOC‑induced increase in LDH‑A expression. The results strongly indicated that LDH‑A serves an important role in DOC resistance in advanced PC cells and inhibition of LDH‑A expression promotes susceptibility to DOC, particularly in CRPC cells. The present study may provide valuable information for developing targeted therapies for CRPC in the future.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Hotte SJ and Saad F: Current management of castrate-resistant prostate cancer. Curr Oncol. 17 (Suppl 2):S72–S79. 2010. View Article : Google Scholar : PubMed/NCBI
3	Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–512. 2004. View Article : Google Scholar : PubMed/NCBI
4	Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
5	Lee BY, Hochgräfe F, Lin HM, Castillo L, Wu J, Raftery MJ, Martin Shreeve S, Horvath LG and Daly RJ: Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol Cancer Ther. 13:190–201. 2014. View Article : Google Scholar : PubMed/NCBI
6	Schwartz L, Supuran CT and Alfarouk KO: The Warburg effect and the Hallmarks of cancer. Anticancer Agents Med Chem. 17:167–170. 2017. View Article : Google Scholar
7	Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, et al: Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 9:332010. View Article : Google Scholar : PubMed/NCBI
8	Yamada Y, Nakamura K, Aoki S, Tobiume M, Zennami K, Kato Y, Nishikawa G, Yoshizawa T, Itoh Y, Nakaoka A, et al: Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer. Oncol Rep. 25:937–944. 2011. View Article : Google Scholar : PubMed/NCBI
9	Goldberg E: Reproductive implications of LDH-C4 and other testis-specific isozymes. Exp Clin Immunogenet. 2:120–124. 1985.PubMed/NCBI
10	Brooks GA, Dubouchaud H, Brown M, Sicurello JP and Butz CE: Role of mitochondrial lactate dehydrogenase and lactate oxidation in the intracellular lactate shuttle. Proc Natl Acad Sci USA. 96:1129–1134. 1999. View Article : Google Scholar : PubMed/NCBI
11	Goldman RD, Kaplan NO and Hall TC: Lactic dehydrogenase in human neoplastic tissues. Cancer Res. 24:389–399. 1964.PubMed/NCBI
12	Zhai X, Yang Y, Wan J, Zhu R and Wu Y: Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol Rep. 30:2983–2991. 2013. View Article : Google Scholar : PubMed/NCBI
13	Hurwitz MD: Chemotherapy and radiation for prostate cancer. Transl Androl Urol. 7:390–398. 2018. View Article : Google Scholar : PubMed/NCBI
14	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
15	García-Castillo V, López-Urrutia E, Villanueva-Sánchez O, Ávila-Rodríguez MÁ, Zentella-Dehesa A, Cortés-González C, López-Camarillo C, Jacobo-Herrera NJ and Pérez-Plasencia C: Targeting metabolic remodeling in triple negative breast cancer in a murine model. J Cancer. 8:178–189. 2017. View Article : Google Scholar : PubMed/NCBI
16	Pelley JW: 6-Glycolysis and Pyruvate Oxidation. Elsevier's Integrated Biochemistry. 47–53. 2007. View Article : Google Scholar
17	Zheng J: Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett. 4:1151–1157. 2012. View Article : Google Scholar : PubMed/NCBI
18	Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M and González-Fernández A: Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 3:3279–3330. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, et al: Primary patient-derived cancer cells and their potential for personalized cancer patient care. Cell Rep. 21:3298–3309. 2017. View Article : Google Scholar : PubMed/NCBI
20	Fadaka A, Ajiboye B, Ojo O, Adewale O, Olayide I and Emuowhochere R: Biology of glucose metabolization in cancer cells. J Oncol Sci. 3:45–51. 2017.
21	Warburg O: On respiratory impairment in cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
22	Kim JW and Dang CV: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930. 2006. View Article : Google Scholar : PubMed/NCBI
23	Chen Z, Lu W, Garcia-Prieto C and Huang P: The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr. 39:267–274. 2007. View Article : Google Scholar : PubMed/NCBI
24	DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB: The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008. View Article : Google Scholar : PubMed/NCBI
25	Kroemer G and Pouyssegur J: Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008. View Article : Google Scholar : PubMed/NCBI
26	Xian ZY, Liu JM, Chen QK, Chen HZ, Ye CJ, Xue J, Yang HQ, Li JL, Liu XF and Kuang SJ: Inhibition of LDHA suppresses tumor progression in prostate cancer. Tumor Biol. 36:8093–8100. 2015. View Article : Google Scholar
27	Vaughn AE and Deshmukh M: Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol. 10:1477–1483. 2008. View Article : Google Scholar : PubMed/NCBI
28	Lu J, Tan M and Cai Q: The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechaism. Cancer Lett. 356:156–164. 2015. View Article : Google Scholar : PubMed/NCBI
29	Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S and Chesney J: Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 10:R842008. View Article : Google Scholar : PubMed/NCBI